If your product’s value lives in where it comes from — a region, a method, a 450-year tradition — the hardest question in your IP strategy is whether the law will let you fence off the name. A recent Federal Court decision answers it for one famous spirit, and the reasoning matters to any business whose brand is bound to a place. In Republic of Peru (Peruvian State) v Registrar of Trade Marks [2026] FCA 791, Burley J allowed Peru’s appeal and ordered acceptance of PISCO as a certification trade mark for alcoholic beverages — the principal route to protecting a geographical indication in Australia. The Registrar had refused it, reasoning that “pisco” signified a grape brandy from either Peru or Chile, so honest Chilean traders might legitimately want the word. The Court disagreed: on the evidence, the ordinary Australian consumer would understand PISCO as denoting a beverage originating in Peru. The decisive factor was not argument but record — roughly 650,000 bottles of Peruvian pisco imported over 14 years, each labelled as a denomination of origin, which the Court found likely to have “educated ordinary consumers as to the connection between Peru and the word PISCO.” The statutory test under s 177 of the Trade Marks Act 1995 (Cth) asks whether the mark is “inherently adapted to distinguish” certified goods, or has become so through use — and Peru’s long, disciplined trail of use carried it.
The strategic lesson is broader than spirits, and it cuts against a common assumption that descriptive or geographic names are simply unregistrable. They are hard to register — but a place-of-origin name can become a protectable, premium-commanding asset if you build the evidentiary and regulatory groundwork early. Three things this case rewards: first, documented use over time — the win came from years of consistent labelling and import records, not from the elegance of the legal submissions, the same “build it before the fight” pattern visible in Built Before the Fight: What May’s IP Decisions Reward. Second, a credible rulebook: a certification mark is only as strong as the production and quality rules behind it, and those rules define who may use the name and on what terms. Third, a realistic view of the monopoly’s edge — the whole fight turned on whether other honest traders need the word, the same boundary between private right and public freedom explored in When the Monopoly Ends, Your Shape Has to Stand on Its Own. For founders and in-house counsel whose value is tied to origin — a regional food, a method, a heritage product — the takeaway is to treat the name as IP from day one: standardise how it appears on every unit, keep the sales and promotion records, and codify the rules before a competitor’s generic use hardens the term against you. Origin can be owned — but only by the business that proves it.
Intellectual property rarely fails loudly. It fails in the gap between filing and follow-through — the priority date no one re-checked, the order no one renewed, the AI agent no one supervised. This month’s posts make one point together: the threat to your most valuable assets is more often your own inattention than a competitor’s attack. Value decays unless someone is actively managing it and documenting it well enough to survive scrutiny.
Precision: A Right Is Only as Strong as Its Weakest Document
Broad and strong are not the same thing. The Full Court’s best-method ruling on divisional strategy showed broadened claims slipping to a later priority date and falling to prior art — the same fragility that, in the US, cost Pfizer’s Paxlovid patent its priority date over a single character, one of three signals from a single week. Precision also decides who keeps an invention: the departing-engineer case was won on the paper trail — assignment clauses, dated records, contemporaneous emails. And in litigation, the discipline runs to your pleadings, where strategic amendments to invalidity grounds rewarded a timely, coherent theory and refused a diffuse one.
Stewardship: Rights You Don’t Work Quietly Lose Their Edge
A site-blocking injunction was extended past its tenth year only after the applicants pruned dead domains and re-certified that the targets were still infringing. Enforcement is an operating commitment, not a trophy. The same logic scales up: the pharmaceutical patent-cliff timetable — ~1,600 extended Australian patents — is effectively a public calendar of competitor exclusivity, engineered years ahead.
The Stewardship Gap Is Now an AI Problem
The burden is shifting fast. The rise of high-impact individual contributors means one person now generates a team’s worth of tacit know-how that walks out the door unless captured. Agentic AI sharpens the edge: your AI agent won’t keep a secret, disclosing confidential information autonomously and leaving discoverable records unlikely to attract privilege — so give it minimum data access, attach provenance, and log its sources. Underwriting all of it is attention at the top, and your IP strategy is only as good as your board’s questions.
What to Watch
The precision standard keeps rising, and the cheapest insurance — clean records, disciplined claims, diarised renewals — is sometimes neglected. The decisions ahead are operational: who monitors filings by former staff, who certifies an order still bites, who governs the AI agents acting on your behalf, and who at board level is asking. Treat IP as a standing discipline, or discover too late what decayed while no one was watching.
For two decades, IP protection quietly relied on one assumption: a human in the loop who knew what was confidential, what was privileged, and where a draft came from. Agentic AI removes that person. A new white paper from the Governance Institute of Australia, Governance in the age of agentic AI, makes the shift plain — agents don’t just generate outputs, they take action. They access databases, draw on sources no reviewer ever sees, and disclose information at machine speed.
The IP consequences look familiar but behave differently. Copyright risk is amplified because the human signing off has less visibility of what the agent drew from. Confidential information can be disclosed autonomously, raising the prospect of breach of confidence without anyone deciding to share anything. And agents produce a large volume of text about their own actions — discoverable, and unlikely to be protected by legal professional privilege.
The strategic takeaway is that deploying an agent is an act of delegation, not a software rollout — and you don’t hand a delegate your trade secrets without limits. For IP-intensive organisations, three disciplines do real work: give agents minimum viable data access (the narrowest permissions needed, revoked when the task ends); attach provenance and a verification status to AI-generated content, so you know what’s been checked; and log inputs, sources and model versions so any output can be traced to its origin.
None of this is a compliance chore — it’s how you capture the upside while keeping the assets that make the business valuable intact.
Worth a read: https://www.governanceinstitute.com.au/advocacy/governance-in-the-age-of-agentic-ai/
The most valuable lesson in intellectual property this week wasn’t a single ruling — it was a pattern. Across a landmark licensing deal, a patent that collapsed over one character, and a Congressional hearing on the rules themselves, the same question kept surfacing: is your IP something you defend, or something you monetise? For in-house counsel, founders and IP leads, that distinction increasingly decides commercial outcomes. A disciplined IP strategy is no longer back-office hygiene. It is how you turn rights into revenue, and how you avoid handing value to a competitor by accident.
Start with the clearest signal. Getty Images announced a multi-year display partnership with OpenAI, putting its licensed images inside ChatGPT — and its share price roughly doubled on the news. Read the structure, not just the headline. Getty, once the loudest litigant against AI image-scraping, carved out a display right and licensed it while keeping training rights separate. That is AI and copyright strategy in practice: granular rights, licensed deliberately, priced as an asset. The durable takeaway for any content owner is that a well-documented, rights-cleared catalogue is now a revenue line inside AI products. The mistake it helps you avoid is treating your library as a single undifferentiated blob — the value sits in your ability to slice rights and license them on your terms.
The second signal is a warning. In Enanta v. Pfizer, the Federal Circuit invalidated patent claims tied to Pfizer’s Paxlovid compound because a one-character gap between the provisional application and the issued claim cost the patent its priority date, letting intervening prior art anticipate it. For anyone who has ever rushed a provisional patent filing, the lesson is blunt: your priority date is only as strong as the literal disclosure in your earliest document. Sloppy drafting is not a clerical risk — it is a commercial one, capable of handing a rival a complete defence. This is exactly where a patent attorney earns their fee, and where in-house counsel should be auditing whether provisionals genuinely describe what the company later claims. Meanwhile, the US House Judiciary IP Subcommittee convened a hearing on whether decades-old copyright and patent frameworks still fit an AI-driven economy — a reminder that the rules underpinning all of this are themselves in motion.
The thread tying the three together is ownership discipline. Know precisely what you own, document it well enough to survive scrutiny, and license it deliberately rather than defensively. The organisations that treat IP strategy as a commercial function — not a compliance afterthought — are the ones converting rights into revenue while others are still litigating.
If you hold copyright in music, film, software or any content that pirates love, a court order blocking the offending site is one of the most effective tools you have — but only if you treat it as a living instrument, not a trophy. The question every rights holder should be asking is not just how to block a copyright-infringing website, but how to keep that block working as the pirates move.
A recent Federal Court decision extending a long-running music industry injunction for a further three years — taking it past the ten-year mark — is a useful reminder of how these orders actually earn their keep. Under section 115A of the Copyright Act, a copyright owner can obtain a carriage service provider injunction requiring ISPs like Telstra, Optus and TPG to disable access to overseas piracy sites. The strategic point sits in the housekeeping: the Court extended the order, but only after pruning dead domain names, swapping out respondents that were no longer carriage service providers, adding new corporate entities, and — notably — requiring the applicants’ solicitors to certify a good-faith belief that the targeted sites were still infringing. The order adapts because the people enforcing it keep feeding the Court accurate facts.
The durable lesson for IP-intensive businesses is that enforcement is an operational commitment, not a one-off win. Pirate operators register fresh domains the moment the old ones are blocked, so the value of a site-blocking order lies in the mechanism that lets you add new pathways by agreement with the ISPs, without running back to court each time — and in the discipline of actually using it.
Three things are worth building into your online piracy enforcement program: a monitoring routine that catches mirror and proxy domains as they appear; a documented, regular review so you can certify in good faith that targets are still live and infringing (and promptly release blocks on those that aren’t); and a diarised renewal well ahead of expiry, because these orders lapse if you let them. The broader principle is one we return to often — a right you don’t actively manage quietly decays. The competitive edge goes to the owner who treats enforcement as a standing process, with the evidence trail to back it.
For related reading, see Repeated infringement and failing to show up gets you 5x damages on how a defendant’s conduct shapes the remedy, IP update: vaccines, counterfeits, textbook piracy and tm translations on the wider piracy and counterfeiting enforcement landscape, and Fast and intuitive IP decision making on making sound enforcement calls under pressure.
Read the full judgment — Universal Music Australia Pty Limited v TPG Internet Pty Ltd (No 2) [2026] FCA 731.
A two-letter ending is a thin defence against a deceptively similar mark. The Federal Court’s decision in On Clouds GmbH v Cyclonic, Inc [2026] FCA 647 overturned the Registrar’s delegate and refused registration of CYCLONIC in Classes 25 and 40, finding it deceptively similar to On Clouds’ earlier CYCLON mark.
Lenehan J’s analysis is a useful reminder of how the notional consumer’s imperfect recollection actually works: the earlier mark sits wholly inside the later one, the first two syllables are identical, and both words gesture toward the same idea — a cyclone. Visual similarity, aural similarity, and shared connotation combined to create a real, tangible risk of confusion, even though “CYCLON” reads as invented and “CYCLONIC” is a known English word. The Court was unpersuaded that consumers would meaningfully distinguish between them at the point of sale, particularly in fast-moving online and physical apparel channels where brand names sit side by side.
For IP‑intensive businesses, the strategic signals are worth pulling out.
First, clearance work needs to test marks against imperfect recollection — not side-by-side comparison — and weight the front of the word heavily, because that is what consumers carry away.
Second, adding a descriptive or grammatical suffix to an existing mark is a fragile differentiation strategy; if the root carries a recognisable idea, the suffix rarely rescues it.
Third, the Class 25 / Class 40 finding on “closely related” goods and services is a quiet but important point: recycling and textile-processing services are now commonly bundled with apparel retail, which expands the conflict zone for fashion brands well beyond their immediate product class.
And finally, the costs outcome — a $125,000 lump sum against a respondent who neither withdrew its application nor filed a submitting notice — underlines that disengagement is not a costless strategy once an appeal is on foot. Disciplined portfolio review, deliberate suffix and family-mark choices, and a clear exit plan when an opposition turns into litigation are all cheaper than the alternative.
Full judgment: https://www.judgments.fedcourt.gov.au/judgments/Judgments/fca/single/2026/2026fca0647
A former engineer leaves, starts a company, and files a patent. Months later the original employer discovers the application describes technology that looks remarkably like a project the engineer worked on internally.
This is one of the more under-managed risks in any R&D-heavy business — and a recent Federal Court decision shows just how fast it can move once it surfaces. The Court ordered the respondents to withdraw a patent application, including filings under the Patent Cooperation Treaty, that claimed priority from technology a former laser engineer had access to during his employment with a defence systems group. The applicant secured an interlocutory injunction — urgent relief granted before trial — on the strength of a serious question that the engineer had misused confidential information under section 183 of the Corporations Act.
The strategic lesson sits underneath the drama: the case was won on the paper trail. Expert evidence aligning the internal concept report with the patent claims, a signed contract assigning IP and defining confidential information, and contemporaneous emails reminding the engineer he could not draw on employer IP — that disciplined record is what made the claim credible enough to justify the order.
The takeaway for in-house IP leads, GCs and founders is that who owns employee inventions in Australia is decided long before a dispute, in the IP clauses in employment contracts and the documentation habits around sensitive projects. Three things are worth checking now: that your contracts assign IP and define confidential information in terms that survive public disclosure; that significant R&D leaves a dated, attributable trail linking people to concepts; and that you monitor patent databases for filings by former staff, because timing is decisive — a forced withdrawal can cost a competitor its priority date permanently, which is exactly why the relief had bite here.
The harder truth is that protecting confidential information from employees is a strategy, not a clause. Once an invention is published, the confidentiality is gone for good, so the value of a strong contract and clean records is that they let you act in the narrow window before that happens.
Read the full judgment — EOS Defence Systems Pty Limited v Pahlavani [2026] FCA 688.
IP Organiser’s recently compiled record of every pharmaceutical patent term extension granted in Australia maps roughly 1,600 extended patents across 850 products, and the patterns are worth reading closely. Activity is concentrated: a handful of originators (Novartis well out in front, then Pfizer, Roche, AstraZeneca and GSK) and just four attorney firms account for around three-quarters of all filings.
The portfolio has also shifted decisively toward biologics and advanced therapies — antibodies, RNAi agents, cell and gene therapies, radioligands and vaccines — using a regime originally built with small molecules in mind. And extension is not a formality: roughly one in eighteen applications was refused or withdrawn, and filings hit a record in 2025 before continuing into 2026. The window to apply is narrow and the eligibility rules unforgiving; the rights go to those who treat timing as a discipline, not an afterthought.
The extended-expiry dates cluster heavily between 2030 and 2034 and stretch out to 2041 — this is, in effect, a published timetable of when each competitor’s protection lapses and when generic or biosimilar entry opens. That is competitive intelligence for challengers and an early-warning system for incumbents. Look closer and you see the architecture: scores of molecules are defended not by one patent but by three or more separately extended patents layered around formulation, salt forms and methods of use. None of this happens by accident.
Lifecycle protection is engineered years ahead — through disciplined filing strategy, deadline rigour and a deliberate stack of rights — the public record will reveal whether you did it well.
Read the calendar and learn from it before your competitors do.
Here’s the data: https://docs.google.com/spreadsheets/d/1wJ7OIdmSfBxNIjJnRDCBNwp2FEiJY74k/edit?gid=920856139#gid=920856139
Here’s Rodney Cruise’s post in LinkedIn: https://www.linkedin.com/feed/update/urn:li:activity:7464445225080557568/
The shift toward high‑impact individual contributors (ICs) is more than an organizational design trend. It signals a deeper structural change in how companies create, protect, and compound value. Elena Verna’s piece on the rise of the HI‑C (link below) shows how AI‑enabled autonomy lets one person deliver what previously required a coordinated team. That’s a productivity story on the surface, but the strategic layer is about control of know‑how, speed of iteration, and the ability to turn insight into defensible advantage before competitors even mobilise.
When individuals can run projects end‑to‑end, the organisation’s IP footprint becomes more fluid — and more dependent on whether leaders have built the systems to capture, protect, and leverage the innovation emerging from these autonomous workflows.
Faster cycles mean more tacit knowledge being created in the flow of work, and more risk that it evaporates or walks out the door if not deliberately captured. The HI‑C model rewards those who can connect craft to commercial outcomes, which is exactly where disciplined IP strategy earns its keep: identifying what is strategically differentiating, locking in ownership early, and ensuring that rapid experimentation doesn’t outpace governance.
The opportunity is clear — a leaner, more empowered organisation can generate more protectable assets, more quickly. The risk is equally clear — without structure, you end up with fragmented know‑how and no defensible position. The takeaway: if you’re flattening your org and accelerating execution, your IP strategy must flatten and accelerate with it.
Read the original article here.
Amending the basis of your validity challenge in patent litigation is never just a procedural move — it is a strategic play with real commercial consequences. What stands out in AstraZeneca AB v Pharmacor Pty Ltd (No 3) [2026] FCA 565 is a good reminder of how timing, clarity of theory, and disciplined framing of invalidity grounds will directly shape the Court’s willingness to let the patent challenger to expand its case.
The Court allowed the obviousness and PTE‑related amendments because they were grounded, timely once recognised, and strategically coherent. But it refused the late‑breaking best‑method case because it was diffuse, exploratory, and would have derailed a tightly scheduled path to trial. Courts reward structured, well‑reasoned strategy and penalise fishing expeditions dressed up in pleadings.
There’s a broader pattern worth noting. As product lifecycles shorten and regulatory‑linked patent extensions become more valuable, the strategic premium on precision increases. This judgment reinforces that your litigation posture is part of your IP strategy — not an afterthought. A party that cannot articulate its theory of invalidity early and with discipline risks losing the opportunity to run it at all.
Conversely, a party that anticipates pressure points early, aligns its technical and legal teams, and builds a coherent narrative is better positioned to protect or challenge market exclusivity.
Treat amendment decisions as strategic investments. The organisations that win are those that structure their IP strategy to move quickly, argue clearly, and keep the commercial timeline front of mind.
You must be logged in to post a comment.